Skip to content
stoqly

Azenta

AZTA Nasdaq Life Sciences Tools & Services Financials FY2016–FY2025

Azenta's revenue rose 3.5% to $594 million in fiscal 2025. Its operating margin was −4.5%, up from −8.9% a year earlier. Free cash flow was $38 million, up 210.3%. The diluted share count fell 13.7%.

Last close · Oct 23, 2026

$36.50

1.4%
Value it Compare
Revenue Total sales reported in the income statement.
$594M
3.6% vs prior year
Operating margin Operating income as a share of revenue.
−4.5%
4.4 pts
Net income Profit after all expenses, interest and tax.
−$55.8M
Free cash flow Cash from operations minus capital spending.
$38.3M
210.3%
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
—
Market cap Last close times the latest diluted share count, so it is approximate.
$1.7B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
—

What Azenta does

No business description yet.

Legal name
AZENTA, INC.
Fiscal year ends
September 30, 2025
Latest annual report
—
Accession · CIK
0001437749-25-036931
0000933974

Revenue and margins

Azenta had $594M of revenue in fiscal 2025, up 3.6% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was $38.3M in fiscal 2025, 6.5% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Azenta returned $0.0M to shareholders in fiscal 2025, 0% of free cash flow. The diluted share count fell 13.7%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Value Azenta yourself

Change the assumptions and see what they imply per share. These are models, not forecasts or price targets — the answer depends entirely on what you put in.

Discounted cash flow

Value per share

—

Adds net cash of — and divides by 45.9M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.

Balance sheet

Cash, debt and the ratios that show how comfortably Azenta can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $228M$1.6B$1.1B$491M$546M
Debt incl. finance leases $50.0M————
Net debt / EBITDA −5.2x————
Debt / equity 0.0x————
Interest coverage −15.3x−5.4x———
Current ratio 2.3x10.7x6.7x4.0x3.0x
Quick ratio 2.1x10.3x6.1x3.7x2.7x
Total assets $1.8B$3.7B$2.9B$2.1B$2.1B
Total liabilities $494M$353M$351M$332M$333M
Shareholders' equity $1.3B$3.4B$2.5B$1.8B$1.7B
Net debt (− = net cash) −$178M————

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.2M

2 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

—

$0.0M

DateInsiderTradeSharesPriceValueFiling
Jul 31, 2026 Ephraim StarrSVP, Gen Counsel & Secretary Bought 335 $24.17 $0.0M Form 4
May 18, 2026 William L CornogDirector Bought 10,000 $16.38 $0.2M Form 4

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY23FY24FY25
Net income is positive ✕ ✕ ✕
Cash from operations is positive ✓ ✓ ✓
Return on assets rose ✕ ✕ ✓
Cash from operations exceeds net income ✓ ✓ ✓
Debt fell relative to assets — — —
Current ratio rose ✕ ✕ ✕
Share count didn't rise ✓ ✓ ✓
Gross margin rose ✕ ✓ ✓
Revenue rose relative to assets ✕ ✓ ✓
F-score — / 9— / 9— / 9
Accruals ratio −0.6%−8.6%−6.2%
Altman Z'' 12.049.679.11

Similar companies

Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.

CompanyMarket capGrowthOp. marginFCF marginROICP/EF-score
Azenta AZTA $1.7B 3.6% −4.5% 6.5% — — —
Bio-Techne TECH $11.4B −0.4% 20.7% 21.7% 9.2% 62.5x 9 Compare →
Medpace MEDP $19.0B 20.0% 21.1% 27.0% — 37.2x 4 Compare →
Bio-Rad Laboratories BIO $9.9B 0.7% 1.8% 14.5% 0.5% 46.3x 5 Compare →
Waters WAT $44.6B 7.0% 25.4% 17.1% 21.0% — 6 Compare →

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $434M $528M $632M $334M $389M $514M $556M $552M $573M $594M
Gross profit $157M $199M $246M $135M $172M $244M $256M $239M $255M $270M
Research and development $44.2M $39.9M $46.9M $17.3M $17.8M $22.4M $27.5M $32.1M $31.5M $30.4M
Operating income −$17.1M $14.3M $31.4M −$47.4M −$36.6M −$31.1M −$24.7M −$61.2M −$51.3M −$26.8M
Interest expense $0.2M $0.4M $9.5M $22.2M $2.9M $2.0M $4.6M $0.0M $0.0M —
Pretax income −$18.1M $14.5M $20.5M −$84.0M −$40.3M −$49.0M −$9.9M −$20.0M −$19.1M −$7.1M
Income tax $66.2M $3.4M −$47.3M −$22.8M −$13.9M −$20.1M $1.3M −$12.0M $5.2M −$31.6M
Net income −$69.5M $62.6M $117M $437M $64.9M $111M $2.1B −$14.6M −$165M −$55.8M
Diluted EPS −$1.01 $0.89 $1.64 $6.04 $0.88 $1.49 $28.48 −$0.22 −$3.10 −$1.22
Diluted shares 0.07B 0.07B 0.07B 0.07B 0.07B 0.07B 0.07B 0.07B 0.05B 0.05B
Cash flow
Cash from operations $39.5M $96.2M $74.0M $90.9M $37.9M $150M −$466M $5.8M $49.7M $72.2M
Capital expenditure $12.8M $12.7M $12.8M $23.9M $39.9M $52.8M $73.4M $39.4M $37.4M $33.9M
Free cash flow $26.7M $83.6M $61.2M $67.0M −$2.1M $97.1M −$539M −$33.6M $12.4M $38.3M
Depreciation and amortization $28.0M $28.1M $37.4M $54.5M $65.5M $65.3M $53.7M $85.6M $90.7M $61.2M
Stock-based compensation $11.7M $17.3M $19.8M $20.1M $16.3M $27.5M $10.7M $9.4M $14.5M $20.9M
Acquisitions $125M $44.8M $85.8M $443M $15.7M $93.7M $126M $387M $0.0M $0.0M
Share buybacks $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $839M $662M $0.0M
Dividends paid $27.5M $27.9M $28.3M $28.9M $29.5M $29.7M $7.5M $0.0M $0.0M $0.0M
Dividends and buybacks $27.5M $27.9M $28.3M $28.9M $29.5M $29.7M $7.5M $839M $662M $0.0M
Balance sheet
Cash and short-term investments $85.1M $102M $244M $291M $251M $228M $1.6B $1.1B $491M $546M
Total debt — — $196M $51.1M $50.4M $49.7M — — — —
Finance lease liabilities $0.0M $0.0M $0.0M $0.0M $1.5M $0.3M $0.2M $2.0M $1.6M $1.5M
Current assets $299M $352M $564M $647M $650M $777M $2.5B $1.4B $833M $708M
Current liabilities $120M $147M $165M $272M $211M $345M $231M $211M $206M $238M
Inventory $92.6M $73.4M $97.0M $99.4M $37.1M $60.4M $85.5M $128M $71.3M $75.0M
Property and equipment, net $54.9M $57.0M $60.0M $101M $88.7M $131M $155M $206M $156M $154M
Total assets $686M $767M $1.1B $1.5B $1.6B $1.8B $3.7B $2.9B $2.1B $2.1B
Total liabilities $132M $159M $377M $377M $346M $494M $353M $351M $332M $333M
Shareholders' equity $554M $608M $718M $1.1B $1.2B $1.3B $3.4B $2.5B $1.8B $1.7B
Margins
Gross margin 36.1% 37.7% 39.0% 40.3% 44.3% 47.5% 46.0% 43.4% 44.4% 45.5%
Operating margin −3.9% 2.7% 5.0% −14.2% −9.4% −6.1% −4.5% −11.1% −8.9% −4.5%
EBITDA margin 2.5% 8.1% 10.9% 2.1% 7.4% 6.7% 5.2% 4.4% 6.9% 5.8%
Net margin −16.0% 11.9% 18.5% 130.9% 16.7% 21.6% 384.0% −2.7% −28.8% −9.4%
FCF margin 6.2% 15.8% 9.7% 20.1% −0.5% 18.9% −97.1% −6.1% 2.2% 6.5%
Returns
Return on capital — — — −4.8% −3.0% −2.3% — — — —
Return on capital employed −2.8% 2.4% 4.1% −4.4% −2.8% −2.2% −1.0% −2.0% −2.3% −1.4%
Return on equity −11.7% 10.8% 17.6% 47.1% 5.5% 8.7% 91.0% −0.5% −7.7% −3.2%
Return on assets −9.6% 8.6% 12.5% 33.5% 4.2% 6.6% 77.1% −0.4% −6.6% −2.7%
Growth
Revenue growth −21.5% 21.5% 19.7% −47.1% 16.3% 32.2% 8.1% −0.7% 4.0% 3.6%
Net income growth −588.6% — 86.2% 275.2% −85.2% 70.8% 1,825.9% −100.7% — —
EPS growth −581.0% — 84.3% 268.3% −85.4% 69.3% 1,811.4% −100.8% — —
FCF growth −3.2% 212.9% −26.8% 9.6% −103.1% — −655.9% — — 210.3%
Share count change −0.1% 2.9% 0.6% 2.0% 2.0% 0.8% 0.6% −11.5% −19.7% −13.7%
Financial health
Net debt / EBITDA — — −0.7x −34.1x −6.9x −5.2x — — — —
Debt / equity — — 0.3x 0.0x 0.0x 0.0x — — — —
Interest coverage −108.6x 35.1x 3.3x −2.1x −12.4x −15.3x −5.4x — — —
Current ratio 2.5x 2.4x 3.4x 2.4x 3.1x 2.3x 10.7x 6.7x 4.0x 3.0x
Quick ratio 1.7x 1.9x 2.8x 2.0x 2.9x 2.1x 10.3x 6.1x 3.7x 2.7x
Capital allocation
Capex / revenue 3.0% 2.4% 2.0% 7.1% 10.3% 10.3% 13.2% 7.2% 6.5% 5.7%
Stock comp / revenue 2.7% 3.3% 3.1% 6.0% 4.2% 5.3% 1.9% 1.7% 2.5% 3.5%
Payouts / FCF 103.0% 33.4% 46.2% 43.1% — 30.6% — — 5,357.5% 0.0%
Quality scores
Piotroski F-score — — — 5.0 5.0 7.0 — — — —
Altman Z'' 0.6 1.3 1.6 3.3 4.2 3.4 15.4 12.0 9.7 9.1
Accruals ratio −15.1% −4.6% 4.6% 26.5% 1.8% −2.3% 93.9% −0.6% −8.6% −6.2%

Source: SEC EDGAR XBRL filings (CIK 0000933974). Data updated October 22, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open